218 related articles for article (PubMed ID: 21045554)
1. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.
Bazzi M; Badros A
Cancer Biol Ther; 2010 Nov; 10(9):830-8. PubMed ID: 21045554
[TBL] [Abstract][Full Text] [Related]
2. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
3. Novel targets and derived small molecule inhibitors in multiple myeloma.
Podar K
Curr Cancer Drug Targets; 2012 Sep; 12(7):797-813. PubMed ID: 22671928
[TBL] [Abstract][Full Text] [Related]
4. Management of myeloma: an Italian perspective.
Bruno B; Gay F; Boccadoro M; Palumbo A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S82-6. PubMed ID: 22035755
[TBL] [Abstract][Full Text] [Related]
5. Spindle cell lesion in the bone marrow.
Guzman S; Kitahara S
Blood; 2018 Sep; 132(10):1085. PubMed ID: 30190353
[No Abstract] [Full Text] [Related]
6. Targeted therapy of multiple myeloma.
Dolloff NG; Talamo G
Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
8. Emerging strategies for targeting cell adhesion in multiple myeloma.
Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA
Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026
[TBL] [Abstract][Full Text] [Related]
9. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
11. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
Bianchi G; Ghobrial IM
Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in multiple myeloma.
Chng WJ; Lau LG; Yusof N; Mow BM
Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapies and combinations for the treatment of multiple myeloma.
Agarwal A; Mahadevan D
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
[TBL] [Abstract][Full Text] [Related]
15. Towards a new age in the treatment of multiple myeloma.
Piazza FA; Gurrieri C; Trentin L; Semenzato G
Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis in multiple myeloma: therapeutic implications.
Chauhan D; Anderson KC
Apoptosis; 2001; 6(1-2):47-55. PubMed ID: 11321040
[TBL] [Abstract][Full Text] [Related]
17. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms in multiple myeloma drug resistance.
Nikesitch N; Ling SC
J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
[TBL] [Abstract][Full Text] [Related]
19. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
Neri P; Bahlis NJ
Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
[TBL] [Abstract][Full Text] [Related]
20. Novel therapies in the treatment of multiple myeloma.
Laubach JP; Mitsiades CS; Mahindra A; Schlossman RL; Hideshima T; Chauhan D; Carreau NA; Ghobrial IM; Raje N; Munshi NC; Anderson KC; Richardson PG
J Natl Compr Canc Netw; 2009 Oct; 7(9):947-60. PubMed ID: 19878638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]